| First Author | Miyakawa K | Year | 2015 |
| Journal | Blood | Volume | 126 |
| Issue | 15 | Pages | 1835-43 |
| PubMed ID | 26179083 | Mgi Jnum | J:230686 |
| Mgi Id | MGI:5763539 | Doi | 10.1182/blood-2014-09-598656 |
| Citation | Miyakawa K, et al. (2015) Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice. Blood 126(15):1835-43 |
| abstractText | Acetaminophen (APAP)-induced liver injury in humans is associated with robust coagulation cascade activation and thrombocytopenia. However, it is not known whether coagulation-driven platelet activation participates in APAP hepatotoxicity. Here, we found that APAP overdose in mice caused liver damage accompanied by significant thrombocytopenia and accumulation of platelets in the liver. These changes were attenuated by administration of the direct thrombin inhibitor lepirudin. Platelet depletion with an anti-CD41 antibody also significantly reduced APAP-mediated liver injury and thrombin generation, indicated by the concentration of thrombin-antithrombin (TAT) complexes in plasma. Compared with APAP-treated wild-type mice, biomarkers of hepatocellular and endothelial damage, plasma TAT concentration, and hepatic platelet accumulation were reduced in mice lacking protease-activated receptor (PAR)-4, which mediates thrombin signaling in mouse platelets. However, selective hematopoietic cell PAR-4 deficiency did not affect APAP-induced liver injury or plasma TAT levels. These results suggest that interconnections between coagulation and hepatic platelet accumulation promote APAP-induced liver injury, independent of platelet PAR-4 signaling. Moreover, the results highlight a potential contribution of nonhematopoietic cell PAR-4 signaling to APAP hepatotoxicity. |
